Northwest Bio SEC Filings

Northwest Biotherapeutics (NWBO) entered into a $5,505,000 commercial loan with Streeterville Capital, LLC. The loan has a 22‑month term, bears 8% annual interest, and includes a 10% original issue discount. There are no repayments for the first eight months, with repayments beginning on June 26, 2026.

After repayments begin, the note amortizes over 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. The company may prepay at its election, subject to a 10% prepayment charge, and the agreement contains customary default and acceleration provisions. Proceeds will support ongoing business operations.

Northwest Biotherapeutics (NWBO) closed its acquisition of Advent BioServices, which is now a wholly owned subsidiary. The deal transfers Advent’s fixed assets, including extensive cryostorage and related equipment, plus intellectual property and other intangibles, to NWBO.

No new shares are being issued. Instead, 19 million previously issued NWBO securities are reverting to the company, comprising 13.5 million shares and 5.5 million options. Cash consideration consists of a payment of £1.4 million and the net amount of accounts payable due to Advent for prior services. Payments will be made in installments over two years, with potential acceleration after regulatory approval of DCVax-L. Installments begin 90 days after the October closing, and the net accounts payable is determined as of the closing date.

Northwest Biotherapeutics (NWBO) reported that it filed a new Form S-3 shelf registration on October 23, 2025 to replace its existing shelf. Shelf registrations expire three years from effectiveness; the company’s current shelf became effective on October 25, 2022 and therefore expires on October 25, 2025. Filing the new shelf before expiration maintains an ongoing effective registration framework.

The company’s common stock trades on the OTCQB under the symbol NWBO.

Northwest Biotherapeutics filed a Form S-3 shelf registration to offer up to $250,000,000 of common stock, preferred stock, depositary shares, warrants, debt securities, share purchase contracts, share purchase units, and units, to be sold from time to time on terms set at each offering. Any specific terms, dealers or underwriters, and expected net proceeds will be detailed in prospectus supplements.

The company states it may use proceeds for general corporate purposes, including working capital, R&D, regulatory and clinical trial expenditures, capital spending, and potential technology acquisitions. NWBO’s common stock trades on the OTCQB under “NWBO”; the last reported sale price was $0.22 on October 20, 2025. As of October 20, 2025, there were 1,528,922,347 shares of common stock issued and outstanding. The public float was $327,321,282 based on 1,487,824,011 non‑affiliate shares at $0.22.

Northwest Biotherapeutics (NWBO) announced a settlement agreement, set out in a binding Term Sheet, to resolve Delaware Court of Chancery litigation over 2020 option awards to management and directors. Under the agreement, 17% of the challenged 2020 options will be cancelled, and the Company’s insurance carriers will pay $2.25 million to the Company.

The parties will use best efforts to complete definitive settlement documents within thirty days, and the settlement is subject to Court approval. The Lead Plaintiff intends to apply for an award of attorneys’ fees and expenses. Under the settlement, the $2.25 million payment is not to be used for any fee award; it is currently anticipated that any fee award will be paid separately by the Company’s insurers.